Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.75 |
| ▸ | ECE1 | P42892 | 12/20 | 0.72 |
| ▸ | CTSC | P53634 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valyltryptophan SCHEMBL30821963 | 1.00 | ACE (0.75) | ACEECE1CTSCALOX15 | |
| Valyltryptophan SCHEMBL30821897 | 1.00 | ACE (0.75) | ACEECE1CTSCALOX15 | |
| Valyltryptophan SCHEMBL150533 | 1.00 | ACE (0.75) | ACEECE1CTSCALOX15 | |
| Valyltryptophan SCHEMBL29365770 | 1.00 | ACE (0.75) | ACEECE1CTSCALOX15 | |
| SCHEMBL30051305 | 0.98 | ACE (0.72) | ACEECE1CTSCALOX15 | |
| SCHEMBL30051858 | 0.96 | ACE (0.69) | ACEECE1CTSCALOX15 | |
| SCHEMBL30051553 | 0.95 | ACE (0.68) | ACEECE1CTSCALOX15 | |
| SCHEMBL30052892 | 0.94 | ACE (0.67) | ACEECE1CTSC | |
| Hydrochloric Acid SCHEMBL11229707 | 0.94 | ACE (0.67) | ACEECE1CTSCALOX15 | |
| Valyltryptophan SCHEMBL30641543 | 0.94 | ACE (0.67) | ACEECE1CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240342237-A1 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | Xygenyx Inc. | 2024-10-17 | — | — | US | claimed |
| CN-101795732-A | Magnolia extract containing compositions | MARY KAY INC | 2010-08-04 | — | — | CN | claimed |
| EP-2144673-A2 | MAGNOLIA EXTRACT CONTAINING COMPOSITIONS | Mary Kay, Inc. (US) | 2010-01-20 | — | — | EP | claimed |
| WO-2008130752-A2 | MAGNOLIA EXTRACT CONTAINING COMPOSITIONS | MARY KAY INC. (US) | 2008-10-30 | — | — | WO | claimed |
| US-20080260869-A1 | Topical skin care; Magnolia extract and other botanical extracts; telangiectasia, puffy eyes, fine lines or wrinkles; reduces or inhibits new capillary formation in or near the treated skin | MARY KAY INC. (US) | 2008-10-23 | — | — | US | claimed |
| US-12485080-B2 | Cosmetic compositions | MARY KAY INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250228912-A1 | COMPOSITION AND METHODS OF TREATMENT FOR SKIN HEALTH AND SLEEP QUALITY USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION | Xygenyx Inc. | 2025-07-17 | — | — | US | disclosed |
| US-20240408101-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Xygenyx Inc. | 2024-12-12 | — | — | US | disclosed |
| US-20240407984-A1 | MAGNOLIA EXTRACT CONTAINING COMPOSITIONS | MARY KAY INC. | 2024-12-12 | — | — | US | disclosed |
| US-20240408115-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Xygenyx Inc. | 2024-12-12 | — | — | US | disclosed |
| US-20240397990-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Xygenyx Inc. | 2024-12-05 | — | — | US | disclosed |
| US-20240398903-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Xygenyx Inc. | 2024-12-05 | — | — | US | disclosed |
| WO-2008130752-A2 | MAGNOLIA EXTRACT CONTAINING COMPOSITIONS | MARY KAY INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130752-A2 | MAGNOLIA EXTRACT CONTAINING COMPOSITIONS | MARY KAY INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080260869-A1 | Topical skin care; Magnolia extract and other botanical extracts; telangiectasia, puffy eyes, fine lines or wrinkles; reduces or inhibits new capillary formation in or near the treated skin | MARY KAY INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080260869-A1 | Topical skin care; Magnolia extract and other botanical extracts; telangiectasia, puffy eyes, fine lines or wrinkles; reduces or inhibits new capillary formation in or near the treated skin | MARY KAY INC. (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2007143006-A2 | POLYMERIC BIOSURFACTANTS | THERAPEUTIC PEPTIDES, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007119741-A1 | NOVEL SWEETENER | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-25 | — | — | WO | disclosed |
| US-7160560-B2 | Skin-care composition | L'OREAL S.A. (FR) | 2007-01-09 | — | — | US | disclosed |
| US-20050089500-A1 | Skin-care composition | L'OREAL S.A. (FR) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260869-A1 | Topical skin care; Magnolia extract and other botanical extracts; telangiectasia, puffy eyes, fine lines or wrinkles; reduces or inhibits new capillary formation in or near the treated skin | CUTA, HIRA, VEGFA | ACE 2946/4885ECE1 1658/4885CTSC 941/4885 |
| US-20240408101-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | CPT2, CPT1A, CPT1B | ACE 1224/4885ECE1 3364/4885CTSC 1144/4885 |
| US-20240398903-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | CPT1B, GGH, FAH | ACE 1155/4885ECE1 3902/4885CTSC 1274/4885 |
| US-20240342237-A1 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | CUTA, PHLPP1, PHLPP2 | ACE 4046/4885ECE1 1737/4885CTSC 249/4885 |
| US-20240408115-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | CNR2, CNR1, HPSE | ACE 684/4885ECE1 1685/4885CTSC 1125/4885 |
| US-20240397990-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | CPT1B, CPT1A, CPT2 | ACE 1168/4885ECE1 2694/4885CTSC 1111/4885 |
| US-12485080-B2 | Cosmetic compositions | HEXA, GLA, HEXB | ACE 2234/4885ECE1 2559/4885CTSC 223/4885 |
| US-20250228912-A1 | COMPOSITION AND METHODS OF TREATMENT FOR SKIN HEALTH AND SLEEP QUALITY USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION | COL2A1, COL1A1, IGFBP1 | ACE 2065/4885ECE1 315/4885CTSC 866/4885 |
| US-20240407984-A1 | MAGNOLIA EXTRACT CONTAINING COMPOSITIONS | GSTO1, GSTA2, GSS | ACE 3778/4885ECE1 4109/4885CTSC 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.